WORCESTER, Mass. — BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. announced a collaboration that provides BIOVECTRA access to Revolution Biomanufacturing’s proprietary platforms for optimizing untranslated regions (UTRs) and codon usage to improve mRNA stability and translation efficiency. The partnership establishes a fully integrated pathway from mRNA sequence design through sterile drug product manufacturing, offering end-to-end development and production capabilities for customers.
Through the partnership, therapeutic developers will be able to move from initial mRNA sequence optimization to process development, scale-up, technology transfer, and GMP manufacturing of plasmid DNA (pDNA), mRNA, lipid nanoparticles (LNP), and sterile drug product for clinical use. The goal is to create a streamlined workflow that reduces delays, supply chain risks, and technical transfer challenges.
“We are thrilled to partner with BIOVECTRA, whose deep experience in GMP manufacturing and commitment to scientific excellence make them an ideal collaborator,” said Molly McGlaughlin, Chief Executive Officer of Revolution Biomanufacturing. “Too often, therapeutic developers lose time and resources coordinating across disconnected suppliers. By integrating Revolution Biomanufacturing’s advanced sequence optimization technologies with BIOVECTRA’s end-to-end GMP manufacturing, we’re creating a clearer, more reliable path from design to drug product for our customers – one that reduces risks tied to supply disruptions, miscommunication, and failed process transfers.”
“This collaboration strengthens our ability to support innovators developing the next generation of mRNA therapeutics,” said Normand Blais, AVP, Product Development of BIOVECTRA. “In pairing Revolution Biomanufacturing’s sequence engineering with BIOVECTRA’s integrated development and manufacturing solutions, we’re helping developers enhance protein expression, determine sequence faster, and move to the clinic with confidence.”
